For neutrophilic, IL-17A-driven patients, escalating ICS doses is unlikely to confer benefit, because IL-17A drives corticosteroid resistance through post-transcriptional mRNA stabilization that bypasses GR transrepression
The FDA says there is no legal basis for selling the compound as a drug, supplement, or food (though there is evidence for its illicit sale and use) (14)
Internal Medicine Expertise: A deep understanding of how sustainable weight loss impacts your long-term health
MetwareBio supports LC-MS-based metabolite analysis, quality control, and pathway-level interpretation for glutathione-related and sulfur amino acid research
10 L of each serial dilution is then added to 90 L of blank plasma for final concentrations of 0.01, 0.02, 0.05, 0.1, 0.2, 1, 10, 20, 50, and 100 g/mL
1, 2026, Blue Cross Blue Shield's standard coverage plans for some employers won't pay for some weight loss medications, the company said in a statement